62377-41-7

Basic information

• Product Name: (S)-3-cyclohexyl-2-hydroxypropionic acid
• Synonyms: (S)-3-cyclohexyl-2-hydroxypropionic acid
• CAS NO: 62377-41-7
• Molecular Weight: 172.224
• Mol File: 62377-41-7.mol

Chemical Properties

• CAS DataBase Reference: (S)-3-cyclohexyl-2-hydroxypropionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-cyclohexyl-2-hydroxypropionic acid(62377-41-7)
• EPA Substance Registry System: (S)-3-cyclohexyl-2-hydroxypropionic acid(62377-41-7)

Safety Data

• Hazardous Substances Data: 62377-41-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Production:
(S)-3-cyclohexyl-2-hydroxypropionic acid is used as a chiral building block for the synthesis of various pharmaceuticals. Its unique structure allows for the creation of drugs with specific therapeutic effects, targeting a range of medical conditions.
Used in Organic Synthesis:
In the field of organic chemistry, (S)-3-cyclohexyl-2-hydroxypropionic acid serves as a key component in the synthesis of complex organic molecules. Its cyclohexyl and hydroxypropionic acid groups facilitate the formation of diverse chemical structures, expanding the scope of possible applications.
Used in Drug Development:
The (S)-enantiomer of (S)-3-cyclohexyl-2-hydroxypropionic acid is particularly valuable in drug development due to its distinct optical and biochemical properties. These properties can be harnessed to create enantiomer-specific drugs, which may exhibit improved efficacy and reduced side effects compared to their racemic counterparts.
Used in the Production of Pharmaceutical Intermediates:
(S)-3-cyclohexyl-2-hydroxypropionic acid is also utilized in the production of pharmaceutical intermediates, which are essential precursors in the synthesis of various drugs. Its presence in these intermediates can influence the final properties of the resulting pharmaceuticals, making it a crucial component in the drug manufacturing process.
Overall, (S)-3-cyclohexyl-2-hydroxypropionic acid is a versatile and important chemical compound with a wide range of applications in the pharmaceutical and chemical industries, from drug development to organic synthesis.

Upstream product

• 5962-91-4 3-cyclohexyl-2-oxo-propionic acid 
• 20312-36-1 L-3-phenyllactic acid 
• 27527-05-5 L-cyclohexylalanine 

Downstream Products

• 216086-95-2 (S)-3-cyclohexyl-2-hydroxy-1-morpholin-4-yl-propan-1-one 
• 140372-02-7 α(S)-Hydroxycyclohexanepropanoic acid phenylmethyl ester 
• 913179-35-8 3-cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-methyl-ethyl]-2-hydroxy-propionamide 
• 849671-38-1 3-cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-2-(S)-hydroxy-propionamide 
• 216088-17-4 (S)-3-cyclohexyl-1,2-propanediol 
• 194551-70-7 (S)-5-Cyclohexyl-4-dibenzylamino-3-oxo-pentanoic acid tert-butyl ester 
• 188775-02-2 (R)-5-Cyclohexyl-4-dibenzylamino-3-oxo-pentanoic acid tert-butyl ester 
• 188774-82-5 (R)-3-Cyclohexyl-2-dibenzylamino-propionic acid methyl ester 
• 188774-88-1 (R)-3-Cyclohexyl-2-dibenzylamino-propionic acid 
• 849670-39-9 [1-(R)-benzyloxymethyl-2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-carbamic acid 1-(S)-cyclohexylmethyl-2-morpholin-4-yl-2-oxo-ethyl ester 

Relevant articles and documents

Enantioselective, Catalytic Vicinal Difluorination of Alkenes

The enantioselective, catalytic vicinal difluorination of alkenes is reported by II/IIII catalysis using a novel, C2-symmetric resorcinol derivative. Catalyst turnover via in situ generation of an ArIIIIF2 species is enabled by Selectfluor oxidation and addition of an inexpensive HF–amine complex. The HF:amine ratio employed in this process provides a handle for regioselective orthogonality as a function of Br?nsted acidity. Selectivity reversal from the 1,1-difluorination pathway (geminal) to the desired 1,2-difluorination (vicinal) is disclosed (>20:1 in both directions). Validation with electron deficient styrenes facilitates generation of chiral bioisosteres of the venerable CF3 unit that is pervasive in drug discovery (20 examples, up to 94:06 e.r.). An achiral variant of the reaction is also presented using p-TolI (up to >95 % yield).

Arylaminoethyl carbamates as a novel series of potent and selective cathepsin S inhibitors

We report a novel series of noncovalent inhibitors of cathepsin S. The synthesis of the peptidomimetic scaffold is described and structure-activity relationships of P3, P1, and P1′ subunits are discussed. Lead optimization to a non-peptidic scaffold has r

COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cathepsin S.

INHIBITORS OF CATHEPSIN S

The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.

INHIBITORS OF CATHEPSIN S

The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also

Biocatalytic racemization of aliphatic, arylaliphatic, and aromatic α-hydroxycarboxylic acids

Biocatalytic racemization of a range of aliphatic, (aryl)aliphatic, and aromatic α-hydroxycarboxylic acids was accomplished by using whole resting cells of a range of Lactobacillus spp. The mild (physiological) reaction conditions ensured an essentially "clean" isomerization in the absence of side reactions, such as elimination or decomposition. Whereas straight-chain aliphatic 2-hydroxy-carboxylic acids were racemized with excellent rates (up to 85% relative to lactate), steric hindrance was observed for branched-chain analogues. Good rates were observed for aryl-alkyl derivatives, such as 3-phenyllactic acid (up to 59%) and 4-phenyl-2-hydroxybutanoic acid (up to 47%). In addition, also mandelate and its o-chloro analogue were accepted at a fair rate (45%). This biocatalytic racemization represents an important tool for the deracemization of a number of pharmaceutically important building blocks.

Biocatalytic racemisation of α-hydroxycarboxylic acids at physiological conditions

Biocatalytic racemisation of aliphatic, aryl-aliphatic and aromatic α-hydroxycarboxylic acids was accomplished using whole resting cells of Lactobacillus paracasei DSM 20207; the mild (physiological) reaction conditions ensured an essentially 'clean' isomerization in the absence of side reactions, such as elimination or decomposition. The Royal Society of Chemistry 2005.

Inhibitors of protein isoprenyl transferases

The present invention relates to novel compounds of Formula I which are useful in inhibiting protein isoprenyl transferases and the farnesylation or geranylgeranylation of the oncogene protein Ras and other related small g-proteins, and compositions containing such compounds and methods of using such compounds.

Inhibitors of protein isoprenyl transferases

Compounds having the formula STR1or a pharmaceutically acceptable salt thereof wherein R 1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L 2 --, and (i) heterocyclic-L 2 --; R 2 is selected from STR2(b) --C(O)NH--CH(R 14)--C(O)OR 15, STR3(d) --C(O)NH--CH(R 14)--C(O)NHSO 2 R 16, (e) --C(O)NH--CH(R 14)-tetrazolyl, (f) --C(O)NH-heterocyclic, and (g) --C(O)NH--CH(R 14)--C(O)NR 17 R 18 ; R 3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R 4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L 1 is absent or is selected from (a) --L 4 --N(R 5)--L 5 --, (b) --L 4 --O--L 5 --, (c) --L 4 --S(O) n --L 5 -- (d) --L 4 --L 6 --C(W)--N(R 5)--L 5 --, (e) --L 4 --L 6 --S(O)m--N(R 5)--L 5 --, (f) --L 4 --N(R 5)--C(W)--L 7 --L 5 --, (g) --L 4 --N(R 5)--S(O) p --L 7 --L 5 --, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.